 |
|
Cheaper HIV Drugs for Poor Nations Bring a New Challenge: Monitoring Treatment
Joan Stephenson, PhD
JAMA. 2002;288:151-153.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
As efforts to make anti-HIV drugs more affordable and available in developing
countries are beginning to pay off, medical experts say it's time to address
a related challenge: Even while more patients are receiving the life-prolonging
therapies, the tests and equipment needed to monitor the effects of their
treatment are out of reach.
Tests that clinicians in wealthier countries consider standard of care,
particularly those used for determining when to initiate drug therapy or whether
a therapeutic regimen is failing to suppress viral replication, are rarely
available—too complex for most laboratories in resource-poor countries
to perform, and too expensive for most patients.
Now, however, a coalition of researchers, physicians, patient advocacy
groups, government agencies, and others is making a concerted effort to develop
and deliver cheap, simple, and effective alternative treatment-monitoring
technologies to improve the medical management of patients on antiretroviral
therapy in developing countries in Africa, . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions
Prado et al.
J. Clin. Microbiol. 2004;42:1620-1625.
ABSTRACT
| FULL TEXT
Meeting the immense need for HAART in resource-poor settings
Bogaards and Goudsmit
J Antimicrob Chemother 2003;52:743-746.
FULL TEXT
AIDS and Antiretroviral Drugs in South Africa: Public Health, Politics, and Individual Suffering: A Review of Brian Tilley's It's My Life
Noah
J Law Med Ethics 2003;31:144-148.
|
